NINDS has just issued a number of funding opportunities covering separately the development of biologics, small molecules and devices in a cooperative manner with the issuing institute (U-Mechanism). This serves a major paradigm shift in NINDS funding.

Further, within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *